SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Smallcap Research

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Rolla Coasta2/19/2005 4:42:18 PM
   of 22
 
Encision's 3Q Revenue Rises 17%
Monday January 24, 6:55 am ET

biz.yahoo.com

BOULDER, Colo., Jan. 24 /PRNewswire-FirstCall/ -- Encision Inc. (Amex: ECI - News), a medical device company with patented surgical technology emerging as a standard of care in minimally-invasive surgery, announced financial results for its third fiscal quarter ended December 31, 2004.
For its third fiscal quarter, Encision's revenues increased by 17% to $2.1 million compared to $1.8 million for last year's third fiscal quarter. Net loss for the third fiscal quarter was $(143,000), or $(0.02) per share, compared to net income of $3,000, or $0.00 per share, for last year's third fiscal quarter. Gross profit as a percent of sales decreased to 56% in the third fiscal quarter versus 59% in the third fiscal quarter of 2003. Operating expenses for the third fiscal quarter this year increased by 26% to $1.33 million compared to $1.06 million in the third fiscal quarter last year.

The increase in operating expenses for the third fiscal quarter this year compared to the third fiscal quarter last year was a result, primarily, of compensation for increased sales employees, increased commissions as a result of higher revenue, and compensation for additional engineers to support development of refinements to the company's product line.

Jack Serino, President and CEO of Encision said, "During the third quarter ended December 31, 2004, we continued to see a trend in increased revenues from sales to new hospital customers and expanded sales in existing hospitals as our network of direct and independent sales representatives became more proficient. We anticipate increased revenue for our full fiscal year that ends March 31, 2005."

Encision Inc. designs, develops, manufactures and markets patented surgical instruments that provide greater safety to patients undergoing minimally-invasive surgery. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext